⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7985567 | 0.93 | — | — | |
| SCHEMBL8018483 | 0.93 | — | — | |
| SCHEMBL6130087 | 0.92 | — | — | |
| SCHEMBL8028142 | 0.92 | — | — | |
| SCHEMBL8031337 | 0.89 | — | — | |
| SCHEMBL8979876 | 0.89 | AGTR1 (0.46) | — | |
| Milfasartan SCHEMBL29486787 | 0.88 | — | — | |
| SCHEMBL8979900 | 0.86 | PPARG (0.42) | — | |
| SCHEMBL7995713 | 0.86 | — | — | |
| SCHEMBL8029901 | 0.85 | AGTR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1064 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-11931341-B2 | Compositions and methods for the treatment and prevention of muscular dystrophy | UNIVERSITY OF LOWA RESEARCH FOUNDATION (US) | 2024-03-19 | — | — | US | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | claimed |
| US-6984633-B2 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone | G.D SEARLE & CO. (US) | 2006-01-10 | — | — | US | claimed |
| WO-2006000564-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND AT1-RECEPTOR ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-01-05 | — | — | WO | claimed |
| US-20050288272-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-12-29 | — | — | US | claimed |
| EP-1545540-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| WO-2004017896-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1393722-A2 | Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome | DePadova, Anthony S. (US) | 2004-03-03 | — | — | EP | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | claimed |
| US-5565464-A | Compounds having angiotensine II antagonistic activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-10-15 | — | — | US | claimed |